Heron Therapeutics, Inc. (NASDAQ:HRTX) gapped down prior to trading on Monday . The stock had previously closed at $18.15, but opened at $17.35. Heron Therapeutics shares last traded at $16.35, with a volume of 2357100 shares trading hands.
A number of research analysts have commented on HRTX shares. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a research note on Sunday. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $27.00 target price on shares of Heron Therapeutics in a report on Friday, November 10th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Mizuho reaffirmed a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Finally, Cowen and Company reissued a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research note on Monday, November 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $28.36.
The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.
Several hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC acquired a new position in Heron Therapeutics in the 2nd quarter valued at $78,134,000. Vanguard Group Inc. grew its holdings in shares of Heron Therapeutics by 40.2% during the 1st quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock worth $28,127,000 after purchasing an additional 537,563 shares during the period. State Street Corp boosted its holdings in Heron Therapeutics by 30.7% during the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock valued at $26,822,000 after acquiring an additional 420,113 shares during the period. Perceptive Advisors LLC acquired a new stake in Heron Therapeutics in the 3rd quarter valued at about $5,329,000. Finally, Chartwell Investment Partners LLC acquired a new stake in shares of Heron Therapeutics during the 3rd quarter worth about $2,340,000.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.